OncLive.com· @OncLive · X·· 3 天前评分70
正文 · 原文
🫁 What lung cancer data could shape practice at #ESMO2026?
@BalazsHalmosMD and Dylan Fortman, MD of @umichmedicine, spotlight key SCLC and NSCLC trials, including DeLLphi-305, PERSEE, Krascendo 1, and SAFFRON.
Explore their picks: https://hubs.li/Q04BZgxl0
644 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：OncLive.com · x.com